Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Williamson, E D
Right arrow Articles by Titball, R W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williamson, E D
Right arrow Articles by Titball, R W
Related Collections
Right arrow Drugs
Right arrow Immunology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 62:163-173 (2002)
© 2002 The British Council

Vaccines against dangerous pathogens

E D Williamson and R W Titball

DSTL, Chemical and Biological Sciences, Porton Down, Salisbury, UK

Dangerous pathogens are defined by the UK Health and Safety Executive's advisory committee as category 3 (those which cause severe human disease for which prophylaxis or therapy is usually available) or category 4 (as for category 3, but for which prophylaxis or therapy is not available). Research and development of vaccines for such pathogens is challenging, due to the safety constraints in the manipulation of these pathogens. This chapter discusses the various approaches which can be taken to develop candidate vaccines for these pathogens, including the potential impact of genome sequencing on shortening the time required for R&D. For these pathogens, a direct test of the efficacy of the candidate vaccines in man is not ethical and, therefore, particular emphasis is placed on the demonstration of efficacy in animal models. Emphasis is also placed on the derivation of surrogate markers of efficacy and a demonstration that these correlate with protection in the animal model.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Infect. Immun.Home page
P. A. Arlen, M. Singleton, J. J. Adamovicz, Y. Ding, A. Davoodi-Semiromi, and H. Daniell
Effective Plague Vaccination via Oral Delivery of Plant Cells Expressing F1-V Antigens in Chloroplasts
Infect. Immun., August 1, 2008; 76(8): 3640 - 3650.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. A. Musson, M. Morton, N. Walker, H. M. Harper, H. V. McNeill, E. D. Williamson, and J. H. Robinson
Sequential Proteolytic Processing of the Capsular Caf1 Antigen of Yersinia pestis for Major Histocompatibility Complex Class II-restricted Presentation to T Lymphocytes
J. Biol. Chem., September 8, 2006; 281(36): 26129 - 26135.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
J. Hill, J. E. Eyles, S. J. Elvin, G. D. Healey, R. A. Lukaszewski, and R. W. Titball
Administration of Antibody to the Lung Protects Mice against Pneumonic Plague
Infect. Immun., May 1, 2006; 74(5): 3068 - 3070.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.